Ascendiant Capital Markets Reaffirms Buy Rating for Vivos Therapeutics (NASDAQ:VVOS)

Ascendiant Capital Markets reissued their buy rating on shares of Vivos Therapeutics (NASDAQ:VVOS) in a report released on Wednesday morning,Benzinga reports. Ascendiant Capital Markets currently has a $6.60 target price on the stock.

Separately, Alliance Global Partners cut their target price on Vivos Therapeutics from $8.25 to $6.00 and set a “buy” rating on the stock in a research report on Tuesday, November 19th.

Vivos Therapeutics Stock Performance

Shares of NASDAQ VVOS opened at $3.20 on Wednesday. The firm’s 50-day simple moving average is $2.79 and its 200 day simple moving average is $2.53. The stock has a market cap of $15.47 million, a price-to-earnings ratio of -0.56 and a beta of 7.71. Vivos Therapeutics has a fifty-two week low of $1.91 and a fifty-two week high of $48.79.

Vivos Therapeutics Company Profile

Vivos Therapeutics, Inc, a medical technology company, develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring.